Signaturefd LLC Increases Stock Position in CureVac (NASDAQ:CVAC)

Signaturefd LLC boosted its holdings in shares of CureVac (NASDAQ:CVAC) by 29.2% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 36,140 shares of the company’s stock after acquiring an additional 8,170 shares during the quarter. Signaturefd LLC’s holdings in CureVac were worth $123,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of CVAC. China Universal Asset Management Co. Ltd. boosted its position in CureVac by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 47,568 shares of the company’s stock valued at $162,000 after acquiring an additional 4,425 shares in the last quarter. Barclays PLC purchased a new stake in shares of CureVac during the 3rd quarter worth $67,000. Public Employees Retirement System of Ohio bought a new stake in CureVac during the third quarter valued at about $91,000. Jane Street Group LLC grew its stake in CureVac by 239.0% in the third quarter. Jane Street Group LLC now owns 79,247 shares of the company’s stock valued at $235,000 after purchasing an additional 55,867 shares during the last quarter. Finally, Integrated Wealth Concepts LLC bought a new position in CureVac in the third quarter worth about $35,000. Institutional investors own 17.26% of the company’s stock.

Analyst Ratings Changes

Separately, JMP Securities restated a “market outperform” rating and issued a $16.00 price target on shares of CureVac in a report on Friday, February 14th.

CureVac Stock Down 2.7 %

CureVac stock opened at $2.89 on Monday. CureVac has a 1-year low of $2.22 and a 1-year high of $5.28. The business has a fifty day moving average price of $3.49 and a 200-day moving average price of $3.19. The company has a debt-to-equity ratio of 0.05, a current ratio of 6.20 and a quick ratio of 6.19. The stock has a market capitalization of $647.01 million, a price-to-earnings ratio of 5.25 and a beta of 2.53.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.